Back to results
US 2021/0196791 A1Published application
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
AssigneeBristol-Myers Squibb Company
InventorsGene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
Claims3
1-75. (canceled)
A modified relaxin polypeptide comprising the structure:
- wherein said AQ1-Relaxin comprises a relaxin A chain polypeptide of SEQ ID NO:
- 35 and a relaxin B chain polypeptide of SEQ ID NO:
- 6, wherein the modified para-acetyl-L-phenylalanine depicted in Formula III is located at the N-terminus of said relaxin A chain polypeptide.
Dependencies are inferred from the claim text.